Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05304962
What this trial is testing

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Regor Pharmaceuticals Inc. 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748208
What this trial is testing

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Who this might be right for
Breast CancerDiabetes Type II
Hoffmann-La Roche 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05565417
What this trial is testing

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Who this might be right for
Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast Cancer+9 more
Immunitas Therapeutics 67
Not applicableNo Longer AvailableNCT02142868
What this trial is testing

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Who this might be right for
Advanced Breast Cancer (Female)
Pfizer
Testing effectiveness (Phase 2)Study completedNCT01177397
What this trial is testing

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Who this might be right for
Multiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more
Celgene 226
Testing effectiveness (Phase 2)WithdrawnNCT00615524
What this trial is testing

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone-receptor Positive Breast Cancer
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT05963997
What this trial is testing

Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 49
Not applicableUnknownNCT02109913
What this trial is testing

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast Cancer
Amsterdam UMC, location VUmc 175
Not applicableWithdrawnNCT05244434
What this trial is testing

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

Who this might be right for
Advanced Breast AdenocarcinomaAdvanced HER2-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8+12 more
City of Hope Medical Center
Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Not applicableStudy completedNCT05399329
What this trial is testing

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Who this might be right for
Breast Cancer
Pfizer 693
Testing effectiveness (Phase 2)Ended earlyNCT00372996
What this trial is testing

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 219
Not applicableUnknownNCT04030728
What this trial is testing

Implementing Patients´ Competence in Oral Breast Cancer Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Onco Medical Consult GmbH 212
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Post-approval studies (Phase 4)Looking for participantsNCT05362760
What this trial is testing

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Who this might be right for
Hormone Receptor-positive Metastatic Breast CancerHER2-negative Metastatic Breast Cancer
Prof. Wolfgang Janni 300
Testing effectiveness (Phase 2)Looking for participantsNCT07647016
What this trial is testing

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Who this might be right for
Breast Cancer
Fudan University 53
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Next Page